Technology titan Philips Healthcare (NYSE:PHG) launched a new telemedicine initiative through a partnership with Vidyo, a New Jersey-based videoconferencing technology provider with a foot in the door at hospitals around the world.
Andover, Mass.-based Philips plans to fold Vidyo’s proprietary adaptive video layering technology into its remote physiologic monitoring and advanced clinical decision support systems, according to a press release.
"We are excited to collaborate with Vidyo to leverage its cutting-edge telepresence technologies to enhance the flexibility and scalability of our telehealth solutions," Philips informatics and patient monitoring senior VP and general manager Mike Mancuso said in prepared remarks. "Philips is committed to working with industry leaders to better address healthcare needs by expanding telehealth services beyond the ICU, as well as externally to remote clinics, physician offices, and into the home."
Biotronik launches MRI-safe pacemaker in Europe
Biotronik said it’s launching its Evia HF-T MRI-safe pacemaker series in Europe.
Read more
BellaNovus inks Ouchless needle distribution deal Down Under
BellaNovus Development Co. said it’s inked a deal to distribute its Ouchless needle in Australia and New Zealand.
Read more
Bio-Matrix forms stem cell subsidiary
Bio-Matrix Scientific (OTC:BMSN) said it’s formed a new subsidiary, Regen BioPharma, to develop stem-cell technologies.
Read more
Medtronic may snag another hypertension devices maker
Med-tech titan Medtronic (NYSE:MDT) may be on the lookout for another possible acquisition in the renal denervation devices arena.
Read more
- Teleheath provider Independa closes $2.35M funding round
- Forus Health raises $5M in Series A
- ProUroCare Medical seeks $1M for diagnostic prostate imaging
- 3M Co. (NYSE:MMM): Deutsche Bank reiterates "hold" rating and $95 price target
- Abiomed (NSDQ:ABMD): Jefferies & Co. raises price target from $25 to $28 from $25, maintains "buy" rating
- Allscripts (NSDQ:MDRX): Credit Suisse downgrades to "neutral" rating, sets $8 price target; UBS downgrades to "neutral" rating; Jeffries downgrades to "hold" rating, sets $10.50 price target; William Blair downgrades to "market perform" rating; Piper Jaffray downgrades to "neutral" rating, sets $11 price target
- Boston Scientific (NYSE:BSX): Leerink maintains "outperform" rating and valuation of about $8 per share
- Covidien (NYSE:COV): Leerink Swann maintains "outperform" rating; Piper Jaffray increases price target from $60 to $64; Bank of America raises price target from $61 to $64;
- HeartWare International (NSDQ:HTWR): UBS maintains its "buy" rating, raises its price target from $95 to $110
- Medtronic (NYSE:MDT): Lazard upgrades to "buy" rating
- Palomar Medical (NSDQ:PMTI): Leerink Swann maintains "market perform" rating and $12 price target
- Smith & Nephew (NYSE:SNN): graf
- Spectranetics (NSDQ:SPNC): Cannacord increases price target from $14.50 to $15.50
- Unilife (NSDQ:UNIS): Leerink Swann grants "outperform" rating
- Zimmer (NYSE:ZMH): Leerink Swann maintains "market perform" rating